Ceo and expert interviews

ImpediMed (ASX:IPD) – early detection of lymphoedema, July 2021

08 Jul 2021 - ImpediMed Limited (ASX:IPD) CEO and Managing Director Richard Carreon discusses the company's bioimpedance spectroscopy platform SOZO, which is particularly targeted at noninvasive clinical assessment and monitoring of fluid status and tissue composition in the treatment of secondary lymphoedema, heart failure and renal failure.